1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Serobian, A.
Thomas, D.S.
Ball, G.E.
Denny, W.A.
Wakelin, L.P.G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C10 H14 N5 O6 P
331.222
y
2'-DEOXYADENOSINE-5'-MONOPHOSPHATE
DNA linking
C9 H14 N3 O7 P
307.197
y
2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE
DNA linking
C10 H14 N5 O7 P
347.221
y
2'-DEOXYGUANOSINE-5'-MONOPHOSPHATE
DNA linking
C10 H15 N2 O8 P
322.208
y
THYMIDINE-5'-MONOPHOSPHATE
DNA linking
C34 H38 N8 O2 4
590.718
1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
non-polymer
US
Biopolymers
BIPMAA
0161
0006-3525
101
1099
10.1002/BIP.22513
24898663
The Solution Structure of Bis(Phenazine-1-Carboxamide)-DNA Complexes: Mln 944 Binding Corrected and Extended.
2014
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
THE DNA CONFORMATION IS IN THE FORM OF B-DNA.
2425.629
DNA
2
syn
polymer
590.718
1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
1
syn
non-polymer
no
no
(DT)(DA)(DT)(DG)(DC)(DA)(DT)(DA)
TATGCATA
A,B
polydeoxyribonucleotide
n
n
n
n
n
n
n
n
20.580
1
20
A
1
B
16
-8.538
A_DT1:DA16_B
1
-2.072
-0.384
-0.431
0.149
8.768
1
20
A
2
B
15
0.322
A_DA2:DT15_B
2
-11.777
0.147
0.121
-0.025
6.401
1
20
A
3
B
14
-5.283
A_DT3:DA14_B
3
-11.104
-0.287
0.010
0.042
-0.957
1
19
A
4
B
13
-0.237
A_DG4:DC13_B
4
-8.007
0.034
0.122
-0.060
-4.085
1
19
A
5
B
12
1.068
A_DC5:DG12_B
5
-9.501
0.203
0.218
-0.026
-3.027
1
20
A
6
B
11
-5.246
A_DA6:DT11_B
6
0.373
0.159
0.177
0.053
5.664
1
20
A
7
B
10
2.924
A_DT7:DA10_B
7
-7.233
-0.145
0.260
-0.055
19.716
1
20
A
8
B
9
1.545
A_DA8:DT9_B
8
-9.077
0.002
-0.007
-0.020
3.992
41.621
A
A
1
2
45.118
B
B
16
15
4.359
29.161
-0.311
1.188
AA_DT1DA2:DT15DA16_BB
1
-0.091
0.140
30.027
-2.980
0.423
3.518
32.851
A
A
2
3
-7.389
B
B
15
14
3.434
-4.167
-0.641
-0.698
AA_DA2DT3:DA14DT15_BB
2
-1.436
2.546
32.562
-0.472
0.871
6.332
12.908
A
A
3
4
-15.157
B
B
14
13
6.955
-3.303
-0.328
0.377
AA_DT3DG4:DC13DA14_BB
3
-4.285
19.662
11.724
9.575
-8.785
3.241
38.767
A
A
4
5
-5.037
B
B
13
12
3.333
-3.339
0.394
0.764
AA_DG4DC5:DG12DC13_BB
4
-1.525
2.300
38.599
1.562
-0.782
5.970
15.216
A
A
5
6
-20.421
B
B
12
11
6.830
-5.284
1.060
0.809
AA_DC5DA6:DT11DG12_BB
5
-1.674
6.468
14.176
11.701
-6.741
3.193
22.312
A
A
6
7
-2.964
B
B
11
10
3.227
-1.145
0.566
-0.338
AA_DA6DT7:DA10DT11_BB
6
-1.561
4.040
22.229
-0.453
-2.038
3.348
45.475
A
A
7
8
2.759
B
B
10
9
3.275
2.129
0.533
0.902
AA_DT7DA8:DT9DA10_BB
7
4.569
-5.922
45.209
0.976
-0.280
repository
Initial release
Structure summary
Structure summary
Database references
1
0
2013-08-21
1
1
2013-08-28
1
2
2013-09-04
1
3
2014-09-03
SOLUTION STRUCTURE OF MLN 944-DNA COMPLEXES
THE SOLUTION STRUCTURE OF THE MLN 944-D(TACGCGTA)2 COMPLEX
PDBE
Y
PDBE
2013-07-30
REL
XR2
1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
32630
SYNTHETIC CONSTRUCT
sample
NONE
DISTANCE RESTRAINTS
1
1
NOESY
COSY
TOCSY
31P HSQC
15N HSQC
80
mM
5.0
pH
1.0
atm
288.0
K
AMBER - MOLECULAR DYNAMICS
10% WATER/90% D2O
D.A.CASE,ET.AL.
refinement
AMBER
structure solution
TOPSPIN
3.1
700
Bruker
Avance
XR2
17
2
XR2
XR2
17
A
DT
1
n
1
DT
1
A
DA
2
n
2
DA
2
A
DT
3
n
3
DT
3
A
DG
4
n
4
DG
4
A
DC
5
n
5
DC
5
A
DA
6
n
6
DA
6
A
DT
7
n
7
DT
7
A
DA
8
n
8
DA
8
A
DT
9
n
1
DT
9
B
DA
10
n
2
DA
10
B
DT
11
n
3
DT
11
B
DG
12
n
4
DG
12
B
DC
13
n
5
DC
13
B
DA
14
n
6
DA
14
B
DT
15
n
7
DT
15
B
DA
16
n
8
DA
16
B
author_and_software_defined_assembly
PQS
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
DT
1
0.082
SIDE CHAIN
1
A
DA
8
0.064
SIDE CHAIN
1
B
DT
9
0.065
SIDE CHAIN
1
B
DA
10
0.073
SIDE CHAIN
1
B
DT
15
0.084
SIDE CHAIN
1
-3.21
0.50
117.00
113.79
A
A
A
C4
C5
C6
DA
DA
DA
2
2
2
N
1
3.22
0.50
117.70
120.92
A
A
A
C5
C6
N1
DA
DA
DA
2
2
2
N
1
-4.51
0.60
118.60
114.09
A
A
A
N1
C6
N6
DA
DA
DA
2
2
2
N
1
3.19
0.30
108.30
111.49
A
A
A
O4'
C1'
N9
DG
DG
DG
4
4
4
N
1
3.91
0.30
108.30
112.21
A
A
A
O4'
C1'
N1
DC
DC
DC
5
5
5
N
1
-4.24
0.70
121.90
117.66
A
A
A
N3
C2
O2
DC
DC
DC
5
5
5
N
1
4.19
0.30
108.30
112.49
A
A
A
O4'
C1'
N9
DA
DA
DA
6
6
6
N
1
-3.17
0.50
117.00
113.83
A
A
A
C4
C5
C6
DA
DA
DA
6
6
6
N
1
3.80
0.50
117.70
121.50
A
A
A
C5
C6
N1
DA
DA
DA
6
6
6
N
1
-4.06
0.60
118.60
114.54
A
A
A
N1
C6
N6
DA
DA
DA
6
6
6
N
1
2.87
0.30
108.30
111.17
A
A
A
O4'
C1'
N1
DT
DT
DT
7
7
7
N
1
-3.14
0.50
117.00
113.86
A
A
A
C4
C5
C6
DA
DA
DA
8
8
8
N
1
3.47
0.50
117.70
121.17
A
A
A
C5
C6
N1
DA
DA
DA
8
8
8
N
1
-4.71
0.60
118.60
113.89
A
A
A
N1
C6
N6
DA
DA
DA
8
8
8
N
1
3.45
0.30
108.30
111.75
B
B
B
O4'
C1'
N1
DT
DT
DT
9
9
9
N
1
-3.75
0.50
117.00
113.25
B
B
B
C4
C5
C6
DA
DA
DA
10
10
10
N
1
3.35
0.50
117.70
121.05
B
B
B
C5
C6
N1
DA
DA
DA
10
10
10
N
1
-5.22
0.60
118.60
113.38
B
B
B
N1
C6
N6
DA
DA
DA
10
10
10
N
1
-3.72
0.60
122.90
119.18
B
B
B
C6
C5
C7
DT
DT
DT
11
11
11
N
1
3.01
0.30
108.30
111.31
B
B
B
O4'
C1'
N9
DG
DG
DG
12
12
12
N
1
2.39
0.30
108.30
110.69
B
B
B
O4'
C1'
N9
DA
DA
DA
14
14
14
N
1
-3.18
0.50
117.00
113.82
B
B
B
C4
C5
C6
DA
DA
DA
14
14
14
N
1
3.81
0.50
117.70
121.51
B
B
B
C5
C6
N1
DA
DA
DA
14
14
14
N
1
-4.23
0.60
118.60
114.37
B
B
B
N1
C6
N6
DA
DA
DA
14
14
14
N
1
1.83
0.30
108.30
110.13
B
B
B
O4'
C1'
N9
DA
DA
DA
16
16
16
N
1
-3.29
0.50
117.00
113.71
B
B
B
C4
C5
C6
DA
DA
DA
16
16
16
N
1
4.03
0.50
117.70
121.73
B
B
B
C5
C6
N1
DA
DA
DA
16
16
16
N
1
-4.16
0.60
118.60
114.44
B
B
B
N1
C6
N6
DA
DA
DA
16
16
16
N
5'-D(*TP*AP*TP*GP*CP*AP*TP*A)-3', 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM
The Solution Structure of the MLN 944-d(TATGCATA)2 Complex
1
N
N
1
N
N
2
N
N
hydrog
WATSON-CRICK
A
DT
1
A
N3
DT
1
1_555
B
DA
16
B
N1
DA
8
1_555
hydrog
WATSON-CRICK
A
DT
1
A
O4
DT
1
1_555
B
DA
16
B
N6
DA
8
1_555
hydrog
WATSON-CRICK
A
DA
2
A
N1
DA
2
1_555
B
DT
15
B
N3
DT
7
1_555
hydrog
WATSON-CRICK
A
DA
2
A
N6
DA
2
1_555
B
DT
15
B
O4
DT
7
1_555
hydrog
WATSON-CRICK
A
DT
3
A
N3
DT
3
1_555
B
DA
14
B
N1
DA
6
1_555
hydrog
WATSON-CRICK
A
DT
3
A
O4
DT
3
1_555
B
DA
14
B
N6
DA
6
1_555
hydrog
WATSON-CRICK
A
DG
4
A
N1
DG
4
1_555
B
DC
13
B
N3
DC
5
1_555
hydrog
WATSON-CRICK
A
DG
4
A
N2
DG
4
1_555
B
DC
13
B
O2
DC
5
1_555
hydrog
WATSON-CRICK
A
DG
4
A
O6
DG
4
1_555
B
DC
13
B
N4
DC
5
1_555
hydrog
WATSON-CRICK
A
DC
5
A
N3
DC
5
1_555
B
DG
12
B
N1
DG
4
1_555
hydrog
WATSON-CRICK
A
DC
5
A
N4
DC
5
1_555
B
DG
12
B
O6
DG
4
1_555
hydrog
WATSON-CRICK
A
DC
5
A
O2
DC
5
1_555
B
DG
12
B
N2
DG
4
1_555
hydrog
WATSON-CRICK
A
DA
6
A
N1
DA
6
1_555
B
DT
11
B
N3
DT
3
1_555
hydrog
WATSON-CRICK
A
DA
6
A
N6
DA
6
1_555
B
DT
11
B
O4
DT
3
1_555
hydrog
WATSON-CRICK
A
DT
7
A
N3
DT
7
1_555
B
DA
10
B
N1
DA
2
1_555
hydrog
WATSON-CRICK
A
DT
7
A
O4
DT
7
1_555
B
DA
10
B
N6
DA
2
1_555
hydrog
WATSON-CRICK
A
DA
8
A
N1
DA
8
1_555
B
DT
9
B
N3
DT
1
1_555
hydrog
WATSON-CRICK
A
DA
8
A
N6
DA
8
1_555
B
DT
9
B
O4
DT
1
1_555
DNA
BIS(PHENAZINE-1-CARBOXAMIDES), MLN 944, DNA, INTERCALATION, DRUG DESIGN, ANTICANCER DRUG.
4BZU
PDB
1
4BZU
1
8
4BZU
1
8
4BZU
A
1
1
8
9
16
4BZU
9
16
4BZU
B
1
1
8
BINDING SITE FOR RESIDUE XR2 A 17
Software
8
A
DT
3
A
DT
3
8
1_555
A
DG
4
A
DG
4
8
1_555
A
DC
5
A
DC
5
8
1_555
A
DA
6
A
DA
6
8
1_555
B
DT
11
B
DT
3
8
1_555
B
DG
12
B
DG
4
8
1_555
B
DC
13
B
DC
5
8
1_555
B
DA
14
B
DA
6
8
1_555
1
P 1